Pacira BioSciences (PCRX) 8-K: Q3 2025 results press release

Pacira BioSciences, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

Pacira BioSciences, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The full text is included as Exhibit 99.1.

The company states the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. PCRX common stock trades on the Nasdaq Global Select Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pacira BioSciences (PCRX) announce in this 8-K?

It furnished a press release with financial results for the third quarter ended September 30, 2025, as Exhibit 99.1.

Where can I find the detailed Q3 2025 results for PCRX?

In the press release filed as Exhibit 99.1 to the current report.

Is the Q3 2025 information considered 'filed' with the SEC?

No. The company states Item 2.02 and Exhibit 99.1 are furnished and not deemed filed under the Exchange Act.

What is Pacira BioSciences’ trading symbol and exchange?

The common stock trades under PCRX on the Nasdaq Global Select Market.

What is the report date for this Pacira 8-K?

The report is dated November 6, 2025.

Which SEC item does this 8-K relate to?

Item 2.02: Results of Operations and Financial Condition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 04:04 PM Learn about SEC filing dates

0001396814false00013968142025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 6, 2025

PACIRA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35060

51-0619477

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2000 Sierra Point Parkway, Suite 900

Brisbane, California 94005

(Address and Zip Code of Principal Executive Offices)

(650) 242-8052

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PCRX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, Pacira BioSciences, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit Number						Description
99.1						Earnings Press Release dated November 6, 2025.
104						Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									PACIRA BIOSCIENCES, INC. (REGISTRANT)
Dated:			November 6, 2025			By:			/s/ KRISTEN WILLIAMS
									Kristen Williams
									Chief Administrative Officer and Secretary